OXFORD CANNABINOID TECHNOLOGIES HOLDINGS PLC Logo

OXFORD CANNABINOID TECHNOLOGIES HOLDINGS PLC

OCTHF | IL

Overview

Corporate Details

ISIN(s):
GB00BMVMRB86
LEI:
2138005SRWT4998BCE35
Country:
United Kingdom
Address:
PRAMA HOUSE, 267 BANBURY ROAD, OX2 7HT OXFORD
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

As of May 2, 2025, Oxford Cannabinoid Technologies Holdings PLC has entered administration and ceased trading. Prior to this, the company operated as a clinical-stage biopharmaceutical firm focused on the research, development, and commercialization of prescription cannabinoid-based medicines. Its primary mission was to create non-addictive therapies for the pain market as alternatives to opioids. The company's research and development efforts targeted the endocannabinoid system (ECS), utilizing a portfolio of compounds that included proprietary derivatives, in-licensed assets, and new chemical entities.

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for OXFORD CANNABINOID TECHNOLOGIES HOLDINGS PLC. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2024-06-06 08:00
Delisting Announcement
Cancellation of Listing
English 10.0 KB
2024-05-31 08:00
Delisting Announcement
Updated Shareholder Engagement
English 10.6 KB
2024-05-17 17:30
Delisting Announcement
Updated Shareholder Information
English 22.6 KB
2024-05-08 08:00
Delisting Announcement
Intended Cancellation of Listing
English 32.1 KB
2024-04-11 12:26
Report Publication Announcement
Appointment of Phase I Clinical Trial CRO
English 17.3 KB
2024-04-03 09:00
Regulatory News Service
OCT Company Update with Doceo
English 7.4 KB
2024-03-26 11:56
Report Publication Announcement
Oxford Cannabinoid Technologies video with Doceo
English 6.9 KB
2024-03-18 08:00
Regulatory News Service
Appointment of Hybridan as Adviser
English 14.2 KB
2024-02-29 08:02
Board/Management Information
Directorate Appointment
English 15.3 KB
2024-02-29 08:01
Board/Management Information
Directorate Changes
English 16.2 KB
2024-02-29 08:00
Declaration of Voting Results & Voting Rights Announcements
Total Voting Rights
English 11.8 KB
2024-02-28 18:35
Major Shareholding Notification
TR-1: NOTIFICATION OF MAJOR HOLDINGS
English 65.2 KB
2024-02-28 18:34
Major Shareholding Notification
TR-1: NOTIFICATION OF MAJOR HOLDINGS
English 71.7 KB
2024-02-28 18:34
Major Shareholding Notification
TR-1: NOTIFICATION OF MAJOR HOLDINGS
English 65.4 KB
2024-02-26 14:07
Director's Dealing
Directors’ Dealings
English 40.8 KB

Automate Your Workflow. Get a real-time feed of all OXFORD CANNABINOID TECHNOLOGIES HOLDINGS PLC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for OXFORD CANNABINOID TECHNOLOGIES HOLDINGS PLC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
FARON PHARMACEUTICALS OY Logo
Develops myeloid cell-targeting immunotherapies for solid and hematological cancers.
Finland FARN
Fluicell AB Logo
Developing bioprinted tissues for regenerative medicine and advanced drug screening.
Sweden FLUI
FluoGuide A/S Logo
Develops fluorescent drugs to guide surgeons for more precise cancer removal and patient outcomes.
Denmark FLUO
FUSION ANTIBODIES PLC Logo
A CRO providing end-to-end antibody engineering services for therapeutic & diagnostic development.
United Kingdom FAB
FUTURA MEDICAL PLC Logo
Develops topical sexual health gels, including a fast-acting, over-the-counter ED treatment.
United Kingdom FUM
Gabather AB Logo
Clinical-stage pharma developing GABAA therapeutics for neuropsychiatric disorders.
Sweden GABA
GEIGER COUNTER LIMITED Logo Jersey GCL
Geneuro Logo
Develops HERV-targeting treatments for neurodegenerative and autoimmune diseases.
Switzerland GEM
GENFIT Logo
Biopharma firm developing therapies & diagnostics for rare and severe liver diseases.
France GNFT
GENFLOW BIOSCIENCES PLC Logo
Developing gene therapies to target the aging process in humans and dogs.
United Kingdom GENF